MDX-1100, a fully human anti-CXCL10 (IP-10) antibody, is a high affinity, neutralizing antibody that has entered Phase I clinical trials for the treatment of Ulcerative Colitis (UC). (131.20)
Year: 2007
Type: conference-abstract
Source: The Journal of Immunology
Authors: Michelle Kuhne, Benjamin Preston, Steven Wallace, Sharline Chen, Geetha Vasudevan, Alison Witte, Pina Cardarelli
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4313387397